Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Medtronic
Cantor Fitzgerald
Citi
Julphar
McKinsey

Generated: March 24, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LUBIPROSTONE

« Back to Dashboard

Clinical Trials for Lubiprostone

Trial ID Title Status Sponsor Phase Summary
NCT00380250 Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation Completed Takeda Phase 3 The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
NCT00380250 Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation Completed Sucampo Pharmaceuticals, Inc. Phase 3 The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
NCT00399542 Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation Completed Takeda Phase 3 The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lubiprostone

Condition Name

Condition Name for Lubiprostone
Intervention Trials
Constipation 14
Chronic Idiopathic Constipation 7
Irritable Bowel Syndrome 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lubiprostone
Intervention Trials
Constipation 29
Irritable Bowel Syndrome 7
Syndrome 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lubiprostone

Trials by Country

Trials by Country for Lubiprostone
Location Trials
United States 342
United Kingdom 11
Canada 10
Mexico 8
Korea, Republic of 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lubiprostone
Location Trials
Texas 16
California 14
Alabama 14
Florida 14
Tennessee 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lubiprostone

Clinical Trial Phase

Clinical Trial Phase for Lubiprostone
Clinical Trial Phase Trials
Phase 4 10
Phase 3 19
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lubiprostone
Clinical Trial Phase Trials
Completed 30
Active, not recruiting 6
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lubiprostone

Sponsor Name

Sponsor Name for Lubiprostone
Sponsor Trials
Takeda 23
Takeda Pharmaceuticals North America, Inc. 10
Sucampo Pharmaceuticals, Inc. 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lubiprostone
Sponsor Trials
Industry 61
Other 24
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Moodys
Johnson and Johnson
US Department of Justice
Chinese Patent Office
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.